367 related articles for article (PubMed ID: 31764118)
1. Targeted Therapy in Chronic Lymphocytic Leukemia.
Kipps TJ; Choi MY
Cancer J; 2019; 25(6):378-385. PubMed ID: 31764118
[TBL] [Abstract][Full Text] [Related]
2. Role of Bruton's tyrosine kinase in B cells and malignancies.
Pal Singh S; Dammeijer F; Hendriks RW
Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis and Treatment of Chronic Lymphocytic Leukemia: A Review.
Shadman M
JAMA; 2023 Mar; 329(11):918-932. PubMed ID: 36943212
[TBL] [Abstract][Full Text] [Related]
4. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
Maddocks K; Jones JA
Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703
[TBL] [Abstract][Full Text] [Related]
5. Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape.
Burger JA
Curr Opin Oncol; 2012 Nov; 24(6):643-9. PubMed ID: 22960555
[TBL] [Abstract][Full Text] [Related]
6. Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies.
ten Hacken E; Burger JA
Pharmacol Ther; 2014 Dec; 144(3):338-48. PubMed ID: 25050922
[TBL] [Abstract][Full Text] [Related]
7. Zanubrutinib: a novel BTK inhibitor in chronic lymphocytic leukemia and non-Hodgkin lymphoma.
Tam CS
Clin Adv Hematol Oncol; 2019 Jan; 17(1):32-34. PubMed ID: 30843894
[No Abstract] [Full Text] [Related]
8. Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies.
Lama TG; Kyung D; O'Brien S
Expert Rev Hematol; 2020 Aug; 13(8):871-883. PubMed ID: 32673127
[TBL] [Abstract][Full Text] [Related]
9. Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.
Ten Hacken E; Burger JA
Biochim Biophys Acta; 2016 Mar; 1863(3):401-413. PubMed ID: 26193078
[TBL] [Abstract][Full Text] [Related]
10. Regulation of MAPK signaling and implications in chronic lymphocytic leukemia.
Shukla A; Shukla V; Joshi SS
Leuk Lymphoma; 2018 Jul; 59(7):1565-1573. PubMed ID: 28882083
[TBL] [Abstract][Full Text] [Related]
11. Targeting the B cell receptor signaling pathway in chronic lymphocytic leukemia.
Patton JT; Woyach JA
Semin Hematol; 2024 Apr; 61(2):100-108. PubMed ID: 38749798
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapies for CLL: Practical issues with the changing treatment paradigm.
Jain N; O'Brien S
Blood Rev; 2016 May; 30(3):233-44. PubMed ID: 26776345
[TBL] [Abstract][Full Text] [Related]
13. Combination of Targeted Drugs to Control Chronic Lymphocytic Leukemia: Harnessing the Power of New Monoclonal Antibodies in Combination With Ibrutinib.
Cramer P; Langerbeins P; Hallek M
Cancer J; 2016; 22(1):62-6. PubMed ID: 26841018
[TBL] [Abstract][Full Text] [Related]
14. Small Molecule Inhibitors in Chronic Lymphocytic Lymphoma and B Cell Non-Hodgkin Lymphoma.
Rosenthal A
Curr Hematol Malig Rep; 2017 Jun; 12(3):207-216. PubMed ID: 28439761
[TBL] [Abstract][Full Text] [Related]
15. Paving the way for new agents; is standard chemotherapy part of the treatment paradigm for chronic lymphocytic leukemia in the future?
Frustaci AM; Montillo M; Picardi P; Mazzucchelli M; Cairoli R; Tedeschi A
Expert Rev Hematol; 2016 Jul; 9(7):679-93. PubMed ID: 27253240
[TBL] [Abstract][Full Text] [Related]
16. Resistance Mechanisms to Targeted Agents in Chronic Lymphocytic Leukemia.
Kittai AS; Woyach JA
Cancer J; 2019; 25(6):428-435. PubMed ID: 31764124
[TBL] [Abstract][Full Text] [Related]
17. Bruton Tyrosine Kinase Inhibitors: Present and Future.
Burger JA
Cancer J; 2019; 25(6):386-393. PubMed ID: 31764119
[TBL] [Abstract][Full Text] [Related]
18. The Evolution of Targeted Therapies in Chronic Lymphocytic Leukaemia.
Gianfelici V; Levato L; Molica S
Curr Hematol Malig Rep; 2020 Aug; 15(4):343-349. PubMed ID: 32500413
[TBL] [Abstract][Full Text] [Related]
19. Targeting B cell receptor signalling in cancer: preclinical and clinical advances.
Burger JA; Wiestner A
Nat Rev Cancer; 2018 Mar; 18(3):148-167. PubMed ID: 29348577
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells.
Purroy N; Carabia J; Abrisqueta P; Egia L; Aguiló M; Carpio C; Palacio C; Crespo M; Bosch F
Oncotarget; 2017 Jan; 8(1):742-756. PubMed ID: 27888629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
